|
Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The human and the chimpanzee TCRG-V9-TCRD-V2 lymphocytes show a similar specific proliferative and cytolytic response to human Daudi Burkitt's lymphoma cells.
|
1322863 |
1992 |
|
Adult Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The human and the chimpanzee TCRG-V9-TCRD-V2 lymphocytes show a similar specific proliferative and cytolytic response to human Daudi Burkitt's lymphoma cells.
|
1322863 |
1992 |
|
Childhood Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The human and the chimpanzee TCRG-V9-TCRD-V2 lymphocytes show a similar specific proliferative and cytolytic response to human Daudi Burkitt's lymphoma cells.
|
1322863 |
1992 |
|
leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Rearrangement of the T-cell receptor delta chain (TCRD) gene at 14q11 was demonstrated in the three cases studied, suggesting its involvement in the pathogenesis of these leukemias by alteration of the structure or expression of an unidentified gene(s) on the long arm of chromosome 5.
|
8090032 |
1994 |
|
Celiac Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, the results of the present study provide no evidence that the analyzed TCRD gene contributes substantially to celiac disease susceptibility.
|
8820404 |
1996 |
|
Acute lymphocytic leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
TCRD PCR-assay detected VD1-JD1 or VD2-D2/3 rearrangements in both acute lymphoblastic leukemia and chronic lymphocytic leukemia samples.
|
9459500 |
1998 |
|
Adult Acute Lymphocytic Leukemia
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Thirdly, a striking predominance of immature Ddelta2-Ddelta3 cross-lineage recombinations was observed (seven out of 16 TCRD rearrangements; 44%), whereas more mature Vdelta2-Ddelta3 gene rearrangements occurred less frequently (six out of 16 TCRD rearrangements; 38% vs >70% in pediatric precursor-B-ALL).
|
9665194 |
1998 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
LOH of BRCA1 correlated with medium grade, positive ER status, and family history of cancer; LOH of TP53 correlated with younger age, high grade, positive PgR status, and with tumours from patients without HRT; LOH of TCRD correlated only with family history of cancer.
|
9893667 |
1998 |
|
Malignant neoplasm of endometrium
|
0.010 |
Biomarker
|
disease |
BEFREE |
To investigate the clinical relevance of LOH of BRCA1 (17q21), TP53 (17p13) and TCRD (14q11) in endometrial cancer, polymerase chain reaction (PCR)-based fluorescent DNA technology for the detection of microsatellite polymorphisms was applied.
|
9893667 |
1998 |
|
Neoplasms
|
0.010 |
GeneticVariation
|
group |
BEFREE |
LOH of BRCA1 correlated with medium grade, positive ER status, and family history of cancer; LOH of TP53 correlated with younger age, high grade, positive PgR status, and with tumours from patients without HRT; LOH of TCRD correlated only with family history of cancer.
|
9893667 |
1998 |
|
Endometrial Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To investigate the clinical relevance of LOH of BRCA1 (17q21), TP53 (17p13) and TCRD (14q11) in endometrial cancer, polymerase chain reaction (PCR)-based fluorescent DNA technology for the detection of microsatellite polymorphisms was applied.
|
9893667 |
1998 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
LOH of BRCA1 correlated with medium grade, positive ER status, and family history of cancer; LOH of TP53 correlated with younger age, high grade, positive PgR status, and with tumours from patients without HRT; LOH of TCRD correlated only with family history of cancer.
|
9893667 |
1998 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
TCRD PCR-assay detected VD1-JD1 or VD2-D2/3 rearrangements in both acute lymphoblastic leukemia and chronic lymphocytic leukemia samples.
|
9459500 |
1998 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
The combined results indicate that IGH gene rearrangements in T-ALL are postoncogenic processes, which are absent in T-ALL with deleted TCRD genes and completed TCR alpha (TCRA) gene rearrangements.
|
10361104 |
1999 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Despite heterogeneity in the rearranged TCRG and TCRD genes, we found preferential protein expression of VgammaI (21/30), Jgamma2.3 (19/30) and Cgamma2 (21/30) gene products in the TCRgammadelta+ T-ALL.
|
10025894 |
1999 |
|
Neoplasm, Residual
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Subsequently, we evaluated, whether heteroduplex PCR analysis of rearranged TCRG and TCRD genes can be used for reliable identification of PCR targets for detection of minimal residual disease (MRD).
|
10025893 |
1999 |
|
Precursor B-cell lymphoblastic leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Finally, the heteroduplex PCR data indicate that MRD monitoring with TCRG and/or TCRD targets is possible in approximately 80% of childhood precursor-B-ALL patients; approximately 55% of patients even have two TCRG and/or TCRD targets.
|
10025893 |
1999 |
|
Neoplasm, Residual
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In 11 TEL/AML1-positive patients, the minimal residual disease (MRD) level at the end of induction therapy was quantified in a limiting dilution assay using IGH or TCRD junctional regions as polymerase chain reaction (PCR) targets.
|
11167743 |
2000 |
|
Neoplasm, Residual
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Since the comparison of Ig/TCR gene rearrangements at diagnosis and relapse in our precursor-B-ALL patients did not show significant difference in the stability of different clonal PCR targets (IGH, 70%; IGK, 71%; TCRD, 67%; TCRG, 75%), we conclude that there is no 'preferential' clone-specific target for MRD monitoring.
|
12886245 |
2003 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
A strong expression of in-frame transcripts with truncated BCL11B and TCRD constant region (TRDC) were observed, but in contrast to normal T cells and other T-ALL samples, no wild-type BCL11B transcripts were detected in the T-ALL sample.
|
15668700 |
2005 |
|
Acute lymphocytic leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Therefore, we have analyzed 83 children with acute B-lineage ALL (67 de novo patients and 19 relapses) by PCR analysis for clonal IgH, incomplete TCRD (Vdelta2-Ddelta3 and Ddelta2-Ddelta3) and TCRG rearrangements.
|
16386788 |
2006 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Therefore, we have analyzed 83 children with acute B-lineage ALL (67 de novo patients and 19 relapses) by PCR analysis for clonal IgH, incomplete TCRD (Vdelta2-Ddelta3 and Ddelta2-Ddelta3) and TCRG rearrangements.
|
16386788 |
2006 |
|
Adult Acute Lymphocytic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Therefore, we have analyzed 83 children with acute B-lineage ALL (67 de novo patients and 19 relapses) by PCR analysis for clonal IgH, incomplete TCRD (Vdelta2-Ddelta3 and Ddelta2-Ddelta3) and TCRG rearrangements.
|
16386788 |
2006 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the position of the LMO2 breakpoints in T-ALL in the light of the occurrence of TCRD-LMO2 translocations in normal thymocytes points to a critical role for the exact breakpoint location in determining LMO2 activation levels and the consequent pressure for T-ALL development.
|
17360939 |
2007 |
|
Acute lymphocytic leukemia
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Whereas IGK-Kde and TCRD rearrangements were rare, TCRG rearrangements were present in 50% of cases and involved mainly Vgamma11 or Vgamma9 together with a Jgamma1.3./2.3 gene segment, an unusual combination among t(4;11)-negative B-cell precursor ALL.
|
17287854 |
2007 |